Medicare GLP-1 Coverage 2026: What Part D Now Covers for Weight Loss

What Changed in 2026: The Historic Shift in Medicare GLP-1 Policy

Since Medicare Part D launched in 2006, federal statute categorically excluded weight-loss drugs from coverage. The reasoning was that obesity treatment was considered a lifestyle choice rather than a medical necessity — a position that the scientific community had long challenged but that remained law for nearly two decades.

Two developments broke this barrier. First, the Inflation Reduction Act of 2022 set the stage for broader drug pricing and coverage reforms. Second, and more directly, Novo Nordisk's SELECT cardiovascular outcomes trial — published in the New England Journal of Medicine in late 2023 — demonstrated that semaglutide (Wegovy) reduced major adverse cardiovascular events by 20% in patients with pre-existing cardiovascular disease and obesity. That data gave CMS the regulatory foothold it needed.

CMS finalized a rule change allowing Medicare Part D plans to cover anti-obesity medications (AOMs) for beneficiaries with established cardiovascular disease or certain other qualifying cardiometabolic conditions. This means that for the first time, Medicare beneficiaries can receive coverage for GLP-1 medications specifically for their weight — not only when a diabetes diagnosis is present. For a broader look at the GLP-1 landscape, see our complete GLP-1 guide.

Which GLP-1 Medications Are Covered Under Medicare Part D in 2026?

Coverage depends on two overlapping factors: the FDA indication of the drug, and your specific Part D plan's formulary. Not every drug in the GLP-1 class is covered for weight loss, and not every plan covers every drug.

GLP-1 Medications Most Likely to Be Covered for Weight Loss

• Wegovy (semaglutide 2.4 mg): The primary GLP-1 approved specifically for chronic weight management in adults. Most likely to appear on Part D formularies for the weight-loss/cardiovascular indication. This is the drug studied in the SELECT trial.
• Zepbound (tirzepatide): Eli Lilly's tirzepatide formulation approved for weight loss. Formulary coverage is expanding in 2026 but less uniform than Wegovy at this stage.

GLP-1 Medications Covered for Diabetes (Not Weight Loss Indication)

• Ozempic (semaglutide 0.5–2 mg): Widely covered under Part D for type 2 diabetes. Not indicated for weight loss alone, though it is the same molecule as Wegovy at a lower maximum dose.
• Mounjaro (tirzepatide): Covered for type 2 diabetes under most Part D formularies. Requires a diabetes diagnosis for this coverage path.
• Rybelsus (oral semaglutide): Covered for type 2 diabetes. Not currently indicated for obesity treatment.
• Victoza/Saxenda (liraglutide): Victoza is covered for diabetes; Saxenda (the weight-loss formulation) has limited Part D formulary presence.

Who Qualifies for Medicare GLP-1 Coverage for Weight Loss?

The 2026 Medicare coverage expansion is targeted, not universal. Beneficiaries who are most likely to qualify fall into one of these categories:

• Established cardiovascular disease: Prior heart attack, stroke, confirmed coronary artery disease, peripheral arterial disease, or similar diagnosis. This group is most directly supported by the SELECT trial data.
• Type 2 diabetes with obesity: Can access GLP-1 coverage through the diabetes indication (Ozempic/Mounjaro) or through the cardiovascular pathway if applicable.
• Qualifying BMI plus cardiometabolic condition: Some plans have extended coverage to patients with BMI ≥27 plus hypertension, obstructive sleep apnea, or dyslipidemia. Plan-by-plan variation is significant here.

Who may not qualify: Beneficiaries seeking GLP-1 treatment purely for weight loss without any of the above qualifying conditions may still face coverage denials in 2026. The expansion is meaningful but not yet universal obesity coverage.

For a detailed look at navigating insurance denials, see our guide on appealing GLP-1 insurance denials.

Prior Authorization Requirements for Medicare GLP-1 Coverage

Prior authorization (PA) is a near-universal requirement for GLP-1 medications under Medicare Part D, whether you are accessing them for diabetes or for weight loss. Understanding what is required — and preparing for it — significantly improves your chance of approval.

What Prior Authorization Typically Requires

• Qualifying diagnosis documentation: Current medical records showing cardiovascular disease, type 2 diabetes, or another qualifying cardiometabolic condition.
• BMI documentation: Most plans require BMI ≥30, or ≥27 with a qualifying comorbidity.
• Letter of medical necessity: A statement from your prescribing provider explaining why the specific medication is medically appropriate for your situation.
• Step therapy requirements: Some plans require documentation that you have attempted and failed a prior treatment (such as a structured weight-loss program or a different medication), though CMS has placed some limits on step therapy requirements for protected drug classes.
• Plan-specific clinical criteria: Each plan's clinical policy may have additional requirements. Read the plan's utilization management policy carefully.

PA Timeline

Standard prior authorization decisions are typically required within 72 hours under CMS rules, though urgent requests can be expedited to 24 hours. In practice, timelines vary based on documentation completeness and plan workload. Working with a provider who is experienced in GLP-1 prior authorization significantly improves both speed and approval rates.

Cost-Sharing and Copays Under Medicare Part D

Coverage does not mean free. Even with Medicare Part D covering your GLP-1, out-of-pocket costs can be meaningful — especially in the early months of the year before you hit the annual out-of-pocket cap.

How the 2026 Part D Cost-Sharing Structure Works

Thanks to the Inflation Reduction Act, the Part D benefit was significantly restructured starting in 2025. The traditional four-phase structure (deductible → initial coverage → coverage gap → catastrophic) has been simplified:

Real-World Monthly Cost Estimates for GLP-1 Patients on Part D

Depending on your plan's formulary tier placement for Wegovy or Zepbound, typical monthly out-of-pocket costs during the initial coverage phase range from approximately $50 to $150. For a drug with a list price of roughly $1,100–$1,300 per month, this represents a substantial discount — but it is far from free.

For patients who fill a GLP-1 prescription every month, the $2,000 annual cap could theoretically be reached in as few as 3–6 months. Once that threshold is crossed, your out-of-pocket cost drops to $0 for the rest of the calendar year.

The Donut Hole Is Gone — But GLP-1 Patients Still Need to Plan

Before 2025, Medicare Part D had a notorious "coverage gap" — commonly called the donut hole — where beneficiaries faced dramatically higher cost-sharing for a period after their initial coverage ran out. For anyone taking an expensive specialty drug like a GLP-1, this gap was often financially crushing.

The Inflation Reduction Act eliminated this gap. The restructured benefit flows directly from initial coverage into catastrophic coverage once you reach the $2,000 out-of-pocket threshold. For GLP-1 patients, this is a genuine improvement.

However, the early part of the year — January through the time you reach the $2,000 cap — can still be expensive. Patients who rely on Part D coverage for GLP-1 medications should budget for approximately $50–$150/month during the pre-cap period, plus any applicable deductible in January.

For context on what GLP-1 medications cost outside of insurance, see our breakdown of affordable GLP-1 injection options.

What If Medicare Does Not Cover Your GLP-1?

Not every Medicare beneficiary will qualify under the expanded coverage rules. If your plan denies coverage — or if your plan simply does not include GLP-1 weight-loss medications on its formulary — you have practical alternatives.

Option 1: Compounded GLP-1 Medications Through Telehealth

Compounded semaglutide and tirzepatide are available through telehealth programs at a fraction of brand-name prices. Programs like Trimi offer compounded semaglutide starting at $99/month — often less than what Part D patients pay in copays during the initial coverage phase, even with insurance.

Compounded medications are prepared by licensed compounding pharmacies and contain the same active ingredient as brand-name products. They are not FDA-approved products themselves, but they are legally prescribed and dispensed when brand-name drugs are unavailable or when cost is a documented barrier. For a safety-focused overview, read our article on compounded semaglutide safety in 2026.

Option 2: Appeal the Denial

If your Part D plan denies a GLP-1 prior authorization, you have the right to appeal. Strong appeals are organized around the plan's exact denial language, include updated clinical documentation from your prescribing provider, and address the specific criterion the plan says was not met. See our detailed GLP-1 insurance appeal guide for a step-by-step process.

Option 3: Switch Plans at Open Enrollment

Medicare open enrollment runs October 15 through December 7 each year. If your current Part D plan does not cover GLP-1 medications for weight loss, reviewing formularies during open enrollment and switching to a plan with better GLP-1 coverage is a legitimate strategy. Medicare's Plan Finder tool allows you to search formularies by drug before selecting a plan.

Option 4: Manufacturer Patient Assistance

Novo Nordisk (Wegovy) and Eli Lilly (Zepbound) both operate patient assistance programs for people who meet income and insurance criteria. For Medicare beneficiaries who do not qualify for Part D coverage, these programs may provide free or reduced-cost medication. Eligibility requirements and availability change, so verify directly with the manufacturer.

Practical Steps to Access Medicare GLP-1 Coverage in 2026

1. Confirm your Part D plan's formulary. Log into your plan portal or call your plan's customer service to verify whether Wegovy or Zepbound is covered and at what tier.
2. Gather your qualifying documentation. Compile records showing your cardiovascular diagnosis, BMI measurements, and any relevant cardiometabolic conditions. Your primary care provider or cardiologist can help.
3. Work with a GLP-1-experienced prescriber. A provider who regularly navigates Medicare PA processes is more likely to submit documentation that meets the plan's specific criteria the first time.
4. Request peer-to-peer review if denied. If your initial PA is denied, ask your provider to request a peer-to-peer review with the plan's medical director. This direct conversation frequently leads to reversals.
5. Evaluate alternatives while awaiting approval. If you are waiting on PA or appeal decisions, a compounded GLP-1 program through a telehealth provider can allow you to start treatment without delay. See our best compounded GLP-1 provider comparison for options.

Frequently Asked Questions

Bottom Line

The 2026 Medicare Part D changes represent genuine progress for the millions of older Americans who could benefit from GLP-1 medications. But coverage remains conditional: you need a qualifying cardiovascular or cardiometabolic condition, your plan needs to carry the drug on its formulary, and prior authorization must be approved before you fill your first prescription.

Out-of-pocket costs during the initial coverage phase — roughly $50–$150 per month — are meaningful, though the IRA's $2,000 annual cap provides important relief later in the year. For beneficiaries who do not qualify under the current rules, or who want to avoid the prior authorization process entirely, compounded GLP-1 programs like Trimi starting at $99/month offer a direct, accessible path to the same active medications.

Whether you pursue Part D coverage or a cash-pay compounded program, the best first step is to verify your options with a licensed provider who understands both pathways. See our guide on how to get a GLP-1 prescription online for a practical starting point.